14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
LVTX vs AQST: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Aquestive Therapeutics, Inc. (AQST) is the stronger overall head-to-head candidate over LAVA Therapeutics N.V. (LVTX) in the Tradestie Institutional Equity Comparison Engine, winning 3–5 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LVTX carries a Unified Composite Score of 67.0/100 (BUY) at $1.74 (N/M Forward P/E, -431.9% operating margin), whereas AQST carries 62.9/100 (BUY) at $3.46 (N/M Forward P/E, -114.1% operating margin).
Composite vs. Pillar Nuance: While LVTX currently prints a higher short-term Unified Composite Score (67.0/100 BUY vs. AQST 62.9/100 BUY), AQST captures the overall institutional head-to-head verdict (3–5 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-114.1% vs. -431.9% operating margin) and revenue trajectory (-41.0% vs. +1313.6% YoY).
Technical & Structure Timing Caution: LVTX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3); meanwhile AQST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LVTX vs AQST. Trailing 12-month operating profitability (LVTX -431.9% vs AQST -114.1%) and valuation multiples (LVTX N/M vs AQST N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $465.7M market capitalization and -114.1% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ LVTX vs AQST Key Questions & Quantitative Answers
As of Nov 20, 2026, Aquestive Therapeutics, Inc. (AQST) is the stronger overall head-to-head candidate over LAVA Therapeutics N.V. (LVTX) in the Tradestie Institutional Equity Comparison Engine, winning 3–5 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LVTX carries a Unified Composite Score of 67.0/100 (BUY) at $1.74 (N/M Forward P/E, -431.9% operating margin), whereas AQST carries 62.9/100 (BUY) at $3.46 (N/M Forward P/E, -114.1% operating margin). Composite vs. Pillar Nuance: While LVTX currently prints a higher short-term Unified Composite Score (67.0/100 BUY vs. AQST 62.9/100 BUY), AQST captures the overall institutional head-to-head verdict (3–5 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-114.1% vs. -431.9% operating margin) and revenue trajectory (-41.0% vs. +1313.6% YoY). Technical & Structure Timing Caution: LVTX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3); meanwhile AQST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
AQST leads the Growth & Scale pillar: LVTX posts +1313.6% YoY revenue growth and +0.0% YoY earnings growth on $5.0M TTM revenue (100.0% gross margin, -431.9% operating margin), compared with AQST at -41.0% YoY revenue growth and +0.0% YoY earnings growth on $49M TTM revenue (65.3% gross margin, -114.1% operating margin). On trailing 12-month operating scale, LVTX generates $5.0M in USD-normalized revenue versus $49M for AQST. In operating R&D and SG&A reinvestment, LVTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AQST.
AQST screens cheaper on headline valuation multiples. LVTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.2x EV/Revenue (unreported EBITDA margin), whereas AQST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 8.9x EV/Revenue (-83.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LVTX (-101.5% ROE) versus AQST (0.0% ROE) capital efficiency.
In options market volatility and institutional positioning, LVTX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 49% Vol realized risk). By comparison, AQST carries 87.9% implied volatility (64th %ile, Elevated (60th–80th %ile)), a 0.98x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.89β · 56% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.